Director/PDMR Shareholding

RNS Number : 8588H

Hikma Pharmaceuticals Plc

12 June 2017

 

Hikma Pharmaceuticals PLC - Vesting of LTIP

LONDON, 12 June 2017: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) ("Hikma") (LEI: 549300BNS685UXH4JI75) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 11 June 2017 under the 2005 Long Term Incentive Plan ("LTIP") which was completed on 12 June 2017. These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is £nil.

Notification and public disclosure of transactions by persons discharging managerial responsibilities

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Khalid Nabilsi
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from vesting of the conditional awards on 11 June 2017 under the LTIP.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 12,842
d)	Aggregated information	N/A
e)	Date of the transaction	12 June 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Riad Mishlawi
2	Reason for the notification
a)	Position/status	EU Vice President and Global Head of Injectables
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from vesting of the conditional awards on 11 June 2017 under the LTIP.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 12,521
d)	Aggregated information	N/A
e)	Date of the transaction	12 June 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michael Raya
2	Reason for the notification
a)	Position/status	CEO of West-Ward Pharmaceuticals
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from vesting of the conditional awards on 11 June 2017 under the LTIP.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 19,244
d)	Aggregated information	N/A
e)	Date of the transaction	12 June 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Bassam Kanaan
2	Reason for the notification
a)	Position/status	Chief Strategy and Corporate Development Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from vesting of the conditional awards on 11 June 2017 under the LTIP.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 20,341
d)	Aggregated information	N/A
e)	Date of the transaction	12 June 2017
f)	Place of the transaction	London Stock Exchange (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Majda Labadi
2	Reason for the notification
a)	Position/status	Corporate Vice President for Human Resources and Head of Operations, MENA
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Hikma Pharmaceuticals PLC
b)	LEI	549300BNS685UXH4JI75
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument and identification code	Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083
b)	Nature of the transaction	Shares acquired from vesting of the conditional awards on 11 June 2017 under the LTIP.
c)	Price(s) and volume(s)	Price(s): £nil Volume(s): 9,879
d)	Aggregated information	N/A
e)	Date of the transaction	12 June 2017
f)	Place of the transaction	London Stock Exchange (XLON)

 

END

 

 

DSHBUGDLCDBBGRD